title: Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report.
abstract: Japanese women with low-stage cervical cancer receiving radical hysterectomy and radiotherapy have a good 5-year survival rate. However, women with risk factors such as nodal metastasis may benefit from adjuvant chemotherapy, which was studied in women having surgery alone or surgery plus radiotherapy. Patients having surgery alone (S) (n=623) or surgery and radiotherapy (SR) (n=919) were randomly assigned to receive or not receive oral 5-fluorouracil (5-FU) for 1 year. The effect of various factors on survival was studied by multivariate analysis. Patients who received S obtained no benefit from 5-FU, whereas 5-FU-treated SR patients had significantly better 5-year survival than those not receiving chemotherapy (P=0.043). The SR patients without nodal metastases had a better survival rate if they received 5-FU (P<0.001), whereas those with nodal metastases did not. Oral 5-FU after radical hysterectomy with radiotherapy appears useful for patients with low-stage cervical cancer who have some risk factors but not for those with pelvic lymph node metastases.
authors.affiliation: Department of Obstetrics and Gynecology, Sakai Hospital, Kinki University School of Medicine, Osaka 590-0132, Japan. yamamoto@sakai.med.kindai.ac.jp
authors.forename: Kaichiro
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Rikuichi
authors.initials: R
authors.lastname: Izumi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Hasegawa
authors.forename: Hisayoshi
authors.initials: H
authors.lastname: Nakajima
authors.forename: Kazutomo
authors.initials: K
authors.lastname: Ohashi
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Kudo
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Okuda
authors.forename: Takeshi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Hideki
authors.initials: H
authors.lastname: Origasa
authors.forename: Hajime
authors.initials: H
authors.lastname: Sugimori
mesh_terms: D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007044:Hysterectomy; D007564:Japan; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D012307:Risk Factors; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil